TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00566618

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Phase I: First Cohort = 100 mg PO Daily x 28 days; Next Cohort = Dose Expansion or Reduction Based on Dose Limiting Toxicity (DLT) in Initial Cohort.~Phase II: Recommended Phase II Dose (RP2D) as determined with Phase I.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic Acid
Description: Phase I: First Cohort = 4 mg IV Over 15 min. every 4 Weeks; Next Cohort = Dose Expansion or Reduction Based on Dose Limiting Toxicity (DLT) in Initial Cohort.~Phase II: Recommended Phase II Dose (RP2D) as determined with Phase I.
Study: NCT01225315

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo administered orally twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Setipiprant
Description: ACT-129968 (Dose 1, Dose 2, or Dose 3) administered orally twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Setipiprant
Description: ACT-129968 (Dose 1, Dose 2, or Dose 3) administered orally twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Setipiprant
Description: ACT-129968 (Dose 1, Dose 2, or Dose 3) administered orally twice daily
Study: NCT03304990

Intervention type: OTHER
Intervention: Patients with CA or suspected risk of CA or a family Hx
Description: Patients with Family History of Cancer, (ii) Patients with Clinical and Environmental Risk Factors for Cancer, (iii) Patients with a Suspected or Confirmed Diagnosis of Cancer.

Intervention type: OTHER
Intervention: Patients with CA or suspected risk of CA or a family Hx
Description: Patients with Family History of Cancer, (ii) Patients with Clinical and Environmental Risk Factors for Cancer, (iii) Patients with a Suspected or Confirmed Diagnosis of Cancer.

Intervention type: OTHER
Intervention: Patients with CA or suspected risk of CA or a family Hx
Description: Patients with Family History of Cancer, (ii) Patients with Clinical and Environmental Risk Factors for Cancer, (iii) Patients with a Suspected or Confirmed Diagnosis of Cancer.
Study: NCT03901027

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapeutic Conversation Interventions
Description: Parents (N=31) at the Children's Hospital at the National University Hospital of Iceland, got two sessions of the FAM-SOTC intervention focusing on emotional support, evidence based information and recommendations and on the strengths of family members. The parents meet with the Advanced Practice Nurse at the Children´s Hospital without the child in both sessions, but each session lasted for 45 to 90 minutes. The sessions were offered with 4-8 weeks interval.
Study: NCT05037812

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline injection
Description: Saline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Multimodal injections
Description: 5mg morphine, 500 micrograms epinephrine, and 4ml normal saline (superficial injection).~2.5mg morphine, 40 micrograms clonidine, 15mg ketorolac, and 4ml normal saline (deep injection).
Study: NCT01777802

Intervention type: RADIATION
Intervention: SBRT

Intervention type: RADIATION
Intervention: SBRT

Intervention type: RADIATION
Intervention: SBRT

Intervention type: RADIATION
Intervention: SBRT

Intervention type: RADIATION
Intervention: IMRT

Intervention type: RADIATION
Intervention: IMRT

Intervention type: RADIATION
Intervention: IMRT

Intervention type: RADIATION
Intervention: IMRT

Intervention type: RADIATION
Intervention: Brachytherapy

Intervention type: RADIATION
Intervention: Brachytherapy

Intervention type: RADIATION
Intervention: Brachytherapy

Intervention type: RADIATION
Intervention: Brachytherapy
Study: NCT01257529

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin controlled release, 330 mg, low-fat
Description: A single oral dose of 330 mg controlled release tablet administered following a low-fat evening meal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin controlled release, 330 mg, medium-fat
Description: A single oral dose of 330 mg controlled release tablet administered following a medium-fat evening meal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin controlled release, 330 mg, high-fat
Description: A single oral dose of 330 mg controlled release tablet administered following a high-fat evening meal

Intervention type: DRUG
Group type: OTHER
Intervention: Pregabalin immediate release, 300 mg
Description: A single oral dose of 300 mg immediate release capsule administered following a medium-fat evening meal
Study: NCT02588742

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: Patients in the melatonin group are given 5mg of melatonin at 8 pm the day before surgery, POD#0, POD#1, POD#2, POD#3, POD#4, and POD#5.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients in the control group are given placebo at 8 pm the day before surgery, POD#0, POD#1, POD#2, POD#3, POD#4, and POD#5.
Study: NCT02561000

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PZ-128

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PZ-128

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01547637

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Obturator nerve block
Description: Peripheral obturator nerve block using 10 ml of 2% lidocaine

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Obturator nerve block
Description: Ultrasound guided peripheral obturator nerve block
Study: NCT04134897

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 130 mg/m2 iv day 1, 4 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: 130 mg/m2 iv day 1, 4 cycles
Study: NCT01548183

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle counseling
Description: Weekly SMS assessments of risky sexual encounters with feedback
Study: NCT03567330

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family-based attachment-focused intervention
Description: 5 2-hour biweekly sessions involving parent and/or adolescent(s).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducation
Description: Provides equivalent number of American Cancer Society psychoeducational sessions involving only parents.
Study: NCT00712491

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Three subconjunctival injections of 1320 micrograms sirolimus each.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Three intravitreal injections of 352 micrograms sirolimus each.
Study: NCT04230785

Intervention type: GENETIC
Intervention: Sequencing of circRNA/lncRNA/miRNA
Description: Next generation sequencing and quantitative real-time polymerase chain reaction of circular RNA (circRNA), long non-coding RNA (lncRNA) and micro-RNA (miRNA)

Intervention type: GENETIC
Intervention: Sequencing of circRNA/lncRNA/miRNA
Description: Next generation sequencing and quantitative real-time polymerase chain reaction of circular RNA (circRNA), long non-coding RNA (lncRNA) and micro-RNA (miRNA)
Study: NCT01980082

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefazolin
Description: Antibiotic

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01925378

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nelfinavir
Description: All medications which a patient is taking will be reviewed at each visit, including the screening, day 1, weeks 4,12, 24.~All patients enrolled in the study will receive 1,250 mg twice PO daily for a 24 week duration.
Study: NCT04134897

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 825 mg/m2, bid, per os, only on days of radiation (Monday through Friday)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Pelvic radiotherapy dose: 44 Gy on regional nodes, 50 Gy on primary tumor
Study: NCT01725737

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GlyTI-M

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Comparator: starch
Study: NCT04134897

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rectal cancer surgery
Description: Laparoscopic or open total mesorectal excision

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Rectal cancer surgery
Description: Laparoscopic or open total mesorectal excision

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Description: Pelvic radiotherapy dose: 25 Gy in 5 Gy fractions
Study: NCT00207441

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Arthritis Self management program

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Chronic Disease Self Management Program
Study: NCT01166932

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxycillin/clavulanic acid
Description: 100mg/Kg/day/10 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ceftriaxone/oxacillin
Description: 75 mg/Kg/day/10 days.
Study: NCT02578485

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AVideogame
Description: Participants active video game played by a period of 60 minutes, then remain at rest for the evaluation of post-exercise blood pressure for an additional period of 60 minutes.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SVideogame
Description: Participants sedentary video game played by a period of 60 minutes, then remain at rest for the evaluation of post-exercise blood pressure for an additional period of 60 minutes.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: EMIntensity
Description: Participants performed walking on a treadmill at moderate intensity by a period of 60 minutes, then remain at rest for the evaluation of post-exercise blood pressure for an additional period of 60 minutes.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: EISVideogame
Description: Participants performed walking on a treadmill in intensity similar to the game by a period of 60 minutes, then remain at rest for the evaluation of post-exercise blood pressure for an additional period of 60 minutes.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Control
Description: participants remained at rest for a period of 60 minutes, then remain at rest for the evaluation of post-exercise blood pressure for an additional period of 60 minutes.
Study: NCT04465994

Intervention type: PROCEDURE
Intervention: gastrocnemius turn-down flaps
Description: We classified the patients with acute achilles tendon rupture by type of surgery. The group who received the gastrocnemius turn-down flaps is the intervention group.
Study: NCT02731131

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a
Description: Peginterferon alfa-2a will be administered as 180 micrograms (mcg) once weekly via subcutaneous (SC) injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a
Description: Peginterferon alfa-2a will be administered as 180 micrograms (mcg) once weekly via subcutaneous (SC) injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Ribavirin will be administered as 1000 to 1200 milligrams (mg) per day in divided oral doses.
Study: NCT01141361

Intervention type: PROCEDURE
Intervention: GPS recording(s) of walking capacity in PAD patients
Description: Home-based GPS recording(s) of walking capacity in PAD patients. Two evaluations will be performed. The second evaluation will be performed six months after the initial assessment (test 1) and only for patients with GPS maximal walking distance below 2000 meters at test 1. It is expected that some patients at test 2 will have undergo surgery or endovascular treatment.
Study: NCT05227807

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mouth opening exercise
Description: The intervention group receives an oral exercise intervention, including a 30-minute individual training, a multimedia oral exercise education video along with a print education booklet, and three follow-up phone calls.
Study: NCT04815889

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: PRIMUS parent training Group
Description: The parents offered a PRIMUS Group-based parent support program for 5 half days. This parenting education for preschool children with developmental problems but without the requirement of diagnosis Hellström (2019) has been designed and tested in other parts of the country but not scientifically validated, which can be done in this study. The teachers will be offered a teacher group for half a day together with the parents.~For those families who need more intervention the PLUSS toddler team (from the specialist Healthcare) is established.~The PLUSS toddler team makes a management plan as referral to Habilitation Center, Child and Adolescent Psychiatry, Speech Therapist, or interventions eg:~* Support in the child's everyday environment home / preschool~* Targeted Parent Groups: toilet, sleep, food, everyday structure, handle behavioural problems~* Web courses

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PRIMUS parent training Group
Description: The parents offered a PRIMUS Group-based parent support program for 5 half days. This parenting education for preschool children with developmental problems but without the requirement of diagnosis Hellström (2019) has been designed and tested in other parts of the country but not scientifically validated, which can be done in this study. The teachers will be offered a teacher group for half a day together with the parents.~For those families who need more intervention the PLUSS toddler team (from the specialist Healthcare) is established.~The PLUSS toddler team makes a management plan as referral to Habilitation Center, Child and Adolescent Psychiatry, Speech Therapist, or interventions eg:~* Support in the child's everyday environment home / preschool~* Targeted Parent Groups: toilet, sleep, food, everyday structure, handle behavioural problems~* Web courses
Study: NCT01212237

Intervention type: PROCEDURE
Intervention: fMRI Evaluation
Description: Functional magnetic resonance imaging (fMRI) uses MR imaging to measure the tiny metabolic changes that take place in an active part of the brain. fMRIs are used for many reasons, for example, to determine precisely which part of the brain is handling critical functions such as thought, speech, movement and sensation, to help assess the effects of stroke, trauma or degenerative disease (such as Alzheimer's) on brain function, and to guide the planning of surgery and radiation therapy.
Study: NCT04278326

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vaginal Biopsy
Description: 1. Vaginal biopsies~2. Additional cervical and vaginal biopsies~3. Non invasive cervico-vaginal swab like a smear
Study: NCT05227807

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: routine care including written mouth exercise instructions
Study: NCT04103229

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: The use of different types and volumes of solutions to inflate the catheter balloon
Description: In catheterization procedure, catheter balloon was inflated according to the type and amount of fluid appropriate to the group to which the patient was assigned.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: The use of different types and volumes of solutions to inflate the catheter balloon
Description: In catheterization procedure, catheter balloon was inflated according to the type and amount of fluid appropriate to the group to which the patient was assigned.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: The use of different types and volumes of solutions to inflate the catheter balloon
Description: In catheterization procedure, catheter balloon was inflated according to the type and amount of fluid appropriate to the group to which the patient was assigned.
Study: NCT06720194

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual therapy
Description: Virtual therapy has been applied for four weeks, three times a week. We administered a total of twelve sessions with a duration of 30 minutes each. Prior to virtual therapy experimental group have received kinesitherapy for 15 minutes to improve and prevent muscle spasticity and joint contractures. Therapists recorded the order of the session and they have providen the same external aid to all patients. Two days a week the experimental group have received the conventional treatment for 45 minutes (kinesitherapy, strengthening exercises muscle, trunk control, transfers, standing and walking). In addition to physiotherapy treatment, participants have done occupational therapy 5 days a week (training to perform ADLs, tracking techniques and search, manipulation, reach and grasping of different utensils, etc.), for 30 minutes each session.

Intervention type: OTHER
Group type: OTHER
Intervention: Usual treatment
Description: Patients assigned to the control group have received the conventional treatment five days a week. They have done physiotherapy session and occupational therapy for 45 and 30 minutes a day each one.
Study: NCT04103229

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: The use of different types and volumes of solutions to inflate the catheter balloon
Description: In catheterization procedure, catheter balloon was inflated according to the type and amount of fluid appropriate to the group to which the patient was assigned.
Study: NCT01410838

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Broth
Description: 200 mL of sodium chloride containing broth, consumed three times per day

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Broth
Description: 200 mL of MSG containing broth consumed three times per day
Study: NCT01597206

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Removable partial denture (Chrome Cobalt Distal extension)
Description: For Group A: a distal extension removable denture will be constructed for patients with a reduced posterior dental arch

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: A reduced posterior dental arch
Description: For Group B: Patients with a reduced posterior dental arch will not be provided with a removable denture and will be compared to patients in Group A
Study: NCT01620463

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: Single dose administered subcutaneously at four different dose levels: 2.5, 5.0, 10.0 and 15.0 mcg/kg. Following completion of each dose group, an evaluation will be performed to allow progression to the next dose group

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Single dose administered subcutaneously at four different dose levels: 2.5, 5.0, 10.0 and 15.0 mcg/kg. Following completion of each dose group, an evaluation will be performed to allow progression to the next dose group
Study: NCT04478097

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-330 Tab. and D086 Tab.
Description: 1T

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-330 Tab. and D086 Tab.
Description: 1T

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-330 Tab. and D086 Tab.
Description: 1T

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-333 Tab.
Description: 1T

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-333 Tab.
Description: 1T

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-333 Tab.
Description: 1T
Study: NCT01259544

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: benzoyl-L-tyrosyl-[1-13C]alanine (Bz-Tyr-Ala)
Description: 300 mg of powder form dissolved in one cup of tap water prior to breath test

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: benzoyl-L-tyrosyl-[1-13C]alanine (Bz-Tyr-Ala)
Description: 300 mg of 13 C di peptide in single dose powder form dissolved in one cup of tap water.
Study: NCT02377986

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BIT+in-home decluterring
Description: BIT Workshop + In-home decluttering practice

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: In-Home Decluttering
Description: In-home decluttering practice
Study: NCT02919852

Intervention type: PROCEDURE
Group type: OTHER
Intervention: laparoscopic retrovesical colpopectinopexia
Description: Laparoscopic correction of pelvic organ prolapse using a mesh in retrovesical space with pectineal ligament fixation.
Study: NCT04603989

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HNC042 for Injection
Description: HNC042,freeze-dried powder,multiple ascending doses, Intravenous route Multiple doses, daily for 7 days, doses: 300mg to 1200mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: Placebo , Intravenous route , multiple ascending doses
Study: NCT00102388

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vildagliptin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gliclazide
Study: NCT01971229

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Carbohydrate based drink
Description: After consumption of the test drink to record the insulin response and gastric emptying.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Carbohydrate based drink
Description: After consumption of the test drink to record the insulin response and gastric emptying.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Whey protein based drink
Description: After consumption of the test drink to record the insulin response and gastric emptying.
Study: NCT03165045

Intervention type: DRUG
Intervention: Spiolto® Respimat®
Description: 6 weeks
Study: NCT02378142

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Study: NCT00333320

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: postconditioning
Description: patients were treated by repeated cycles of cycles of reperfusion/ischemia at the end of the procedure within the first minute after reperfusion
Study: NCT01971229

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Whey protein based drink
Description: After consumption of the test drink to record the insulin response and gastric emptying.
Study: NCT03895307

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: kinesio tape
Description: two 15 cm I type kinesio tape applied longitudinally

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: kinesio tape
Description: two 15 cm I type kinesio tape applied longitudinally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: local anesthetic
Description: local anesthetic: 18-20 cc %0.5 lidocaine subcutaneous injection

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: local serum physiologic
Description: serum physiologic : 18-20 cc % 0.09 NaCl subcutaneous injection
Study: NCT03355807

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium
Description: The magnesium group (group Mg, n _ 40) received an additional infusion of MgSO4